Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Cogent Biosciences, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WALTHAM, MASS. AND BOULDER, COLO., NOV. 14, 2025 (GLOBE NEWSWIRE) -- COGENT BIOSCIENCES, INC.(NASDAQ: COGT), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING PRECISION THERAPIES FOR GENETICALLY DEFINED DISEASES, TODAY ANNOUNCED ITS PARTICIPATION IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON ON WEDNESDAY, NOVEMBER 19, 2025 AT 11:30 A.M. GMT (6:30 A.M. ET).

COGENT BIOSCIENCES ANNOUNCES PARTICIPATION IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

WALTHAM, MASS. AND BOULDER, COLO., NOV. 11, 2025 (GLOBE NEWSWIRE) -- COGENT BIOSCIENCES, INC. (COGENT) (NASDAQ: COGT), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING PRECISION THERAPIES FOR GENETICALLY DEFINED DISEASES, TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 9,677,420 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $31.00 PER SHARE (SUCH OFFERING, THE EQUITY OFFERING) AND ITS UNDERWRITTEN PUBLIC OFFERING OF $200.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF ITS 1.625% CONVERTIBLE SENIOR NOTES DUE 2031 (THE CONVERTIBLE NOTES AND SUCH OFFERING, THE CONVERTIBLE NOTES OFFERING). THE EQUITY OFFERING WAS UPSIZED FROM THE PREVIOUSLY ANNOUNCED OFFERING SIZE OF $200.0 MILLION OF SHARES OF COMMON STOCK.

COGENT BIOSCIENCES ANNOUNCES PRICING OF CONCURRENT PUBLIC OFFERINGS OF COMMON STOCK AND 1.625% CONVERTIBLE SENIOR NOTES DUE 2031

COGENT BIOSCIENCES ANNOUNCES PROPOSED CONCURRENT PUBLIC OFFERINGS OF CONVERTIBLE SENIOR NOTES DUE 2031 AND COMMON STOCK

16.5 MONTHS MEDIAN PROGRESSION FREE SURVIVAL (MPFS) FOR BEZUCLASTINIB PLUS SUNITINIB COMPARED TO 9.2 MONTHS MPFS FOR SUNITINIB MONOTHERAPY (HR=0.50, CI: 0.39-0.65; P

COGENT BIOSCIENCES REPORTS POSITIVE RESULTS FROM BEZUCLASTINIB PEAK PHASE 3 TRIAL IN GASTROINTESTINAL STROMAL TUMORS (GIST)

PHASE 3 PEAK RESULTS IN 2 ND -LINE GIST PATIENTS EXPECTED IN NOVEMBER; PIVOTAL APEX RESULTS IN ADVSM PATIENTS EXPECTED IN DECEMBER

COGENT BIOSCIENCES REPORTS RECENT BUSINESS HIGHLIGHTS AND THIRD QUARTER 2025 FINANCIAL RESULTS

SUMMIT DATA FOR BEZUCLASTINIB IN NONADVSM SELECTED FOR TWO ORAL PRESENTATIONS WHICH WILL DESCRIBE ITS BEST-IN-CLASS POTENTIAL NOVEL JAK2 V617F MUTANT-SELECTIVE INHIBITOR ANNOUNCED AS COGENT'S NEWEST PRECLINICAL PROGRAM; ON-TRACK FOR IND IN 2026 WALTHAM, MASS. AND BOULDER, COLO.

COGENT BIOSCIENCES ANNOUNCES MULTIPLE PRESENTATIONS AT THE 67TH ANNUAL AMERICAN SOCIETY OF HEMATOLOGY (ASH) MEETING

WALTHAM, MASS. AND BOULDER, COLO., OCT. 24, 2025 (GLOBE NEWSWIRE) -- COGENT BIOSCIENCES, INC. (NASDAQ: COGT), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING PRECISION THERAPIES FOR GENETICALLY DEFINED DISEASES, TODAY ANNOUNCED UPDATED PRECLINICAL DATA FROM THE COMPANY'S POTENT AND SELECTIVE PAN KRAS(ON) INHIBITOR IN A POSTER PRESENTATION AT THE 2025 AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS TAKING PLACE IN BOSTON, MA, OCTOBER 22-26, 2025.

COGENT BIOSCIENCES ANNOUNCES KRASPOSTER PRESENTATION AT THE2025AACR-NCI-EORTC INTERNATIONALCONFERENCEON MOLECULAR TARGETS AND CANCER THERAPEUTICS

DETAILED RESULTS FROM BEZUCLASTINIB'S POSITIVE SUMMIT TRIAL EVALUATING BEZUCLASTINIB IN PATIENTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS PLANNED FOR PRESENTATION AT UPCOMING SCIENTIFIC CONFERENCE THIS YEAR NDA SUBMISSION FOR BEZUCLASTINIB PLANNED BY YE 2025 WALTHAM, MASS. AND BOULDER, COLO.

Cogent Biosciences, Inc.

COGT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Cogent Biosciences, Inc.

COGT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

COGT